Current advances and challenges in the development of acinetobacter vaccines

Download
  1. Get@NRC: Current advances and challenges in the development of acinetobacter vaccines (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1080/21645515.2015.1052354
AuthorSearch for:
TypeArticle
Journal titleHuman Vaccines and Immunotherapeutics
ISSN2164-5515
Volume11
Issue10
Pages24952500; # of pages: 6
AbstractAcinetobacter baumannii is a major cause of healthcare-associated infections worldwide with high morbidity and mortality. The clinical treatment of A. baumannii infections has become increasingly difficult because of the rapid emerging of multidrug and extremely drug resistant strains. Thus, there is an urgent need for the development of novel intervention strategies to combat this multidrug-resistant pathogen. Vaccine is one of the most effective medical measures for infection control and is likely to overcome the development of multidrug resistance by A. baumannii. Here we discussed the recent advances and potential challenges in development of A. baumannii vaccines with a focus on the 3 most important steps in the preclinical vaccine development: antigen selection, immune correlates of protection, and animal models for efficacy evaluation.
Publication date
PublisherTaylor & Francis Group
LanguageEnglish
AffiliationNational Research Council Canada (NRC-CNRC); Human Health Therapeutics
Peer reviewedYes
NPARC number21277356
Export citationExport as RIS
Report a correctionReport a correction
Record identifier000a6b3b-577a-489c-af95-98f920742674
Record created2016-03-09
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)